Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing ...
Sangamo Therapeutics Inc. and Chroma Medicine Inc. have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for ...
If MARIA predicted that the engineered zinc fingers weren't likely to be seen by the immune system, the design was considered safer. While the combination of these two models did yield functional zinc ...
Understanding of the DNA-binding characteristics of zinc-finger protein transcription factors has made it possible to design ZFPs to bind to specific target sequences and these designed ZFPs have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results